AMP Begins Hypothetical Positions in Two Food Allergy Companies (DBVT & AIMT)


Amidst a down day in the biotech sector, AMP began two positions in food allergy companies DBV Technologies (NASDAQ: DBVT) and Aimmune Therapeutics (NASDAQ: AIMT).

Both companies have Phase 3 assets to treat peanut allergies and expect readouts from those trials by the end of 2017.

AMP purchased $12,500 worth of shares in both companies and now currently holds 583 and 289 shares of AIMT and DBVT respectively.

For more information see:

http://www.aimmune.com/pipeline/

https://www.dbv-technologies.com/en/viaskin-products


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon